KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SAN DIEGO, Feb. 11, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Thursday, February 25, 2016 | |||
| Time: | 4:30 p.m. ET | |||
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) | |||
| Confirmation code: | 49757304 | |||
| Live webcast: | www.retrophin.com in the "Events & Presentations" section of the "Investors" page | |||
A replay of the call will be available 7:30 p.m. ET, February 25, 2016 to 11:59 p.m. ET, March 3, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 49757304.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the company’s marketed products, Chenodal®, Cholbam® and Thiola®.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
